AU2001279515A1 - Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases - Google Patents

Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases

Info

Publication number
AU2001279515A1
AU2001279515A1 AU2001279515A AU7951501A AU2001279515A1 AU 2001279515 A1 AU2001279515 A1 AU 2001279515A1 AU 2001279515 A AU2001279515 A AU 2001279515A AU 7951501 A AU7951501 A AU 7951501A AU 2001279515 A1 AU2001279515 A1 AU 2001279515A1
Authority
AU
Australia
Prior art keywords
disease
dementia
tissue
body fluid
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001279515A
Other languages
English (en)
Inventor
Hyman M. Schipper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sir Mortimer B Davis Jewish General Hospita
Original Assignee
Sir Mortimer B Davis Jewish General Hospita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sir Mortimer B Davis Jewish General Hospita filed Critical Sir Mortimer B Davis Jewish General Hospita
Publication of AU2001279515A1 publication Critical patent/AU2001279515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
AU2001279515A 2000-07-25 2001-07-25 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases Abandoned AU2001279515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22081300P 2000-07-25 2000-07-25
US60/220,813 2000-07-25
PCT/CA2001/001066 WO2002008449A2 (fr) 2000-07-25 2001-07-25 Suppresseur de ho-1 utile comme test de diagnostic et de pronostic dans les maladies dementielles

Publications (1)

Publication Number Publication Date
AU2001279515A1 true AU2001279515A1 (en) 2002-02-05

Family

ID=22825083

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001279515A Abandoned AU2001279515A1 (en) 2000-07-25 2001-07-25 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases

Country Status (9)

Country Link
US (1) US7105485B2 (fr)
EP (1) EP1303537B1 (fr)
JP (1) JP2004504366A (fr)
AT (1) ATE340805T1 (fr)
AU (1) AU2001279515A1 (fr)
CA (1) CA2417134A1 (fr)
DE (1) DE60123431D1 (fr)
IL (1) IL154093A0 (fr)
WO (1) WO2002008449A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9100457B2 (en) 2001-03-28 2015-08-04 Qualcomm Incorporated Method and apparatus for transmission framing in a wireless communication system
US7352868B2 (en) 2001-10-09 2008-04-01 Philip Hawkes Method and apparatus for security in a data processing system
US20040191803A1 (en) * 2002-11-22 2004-09-30 Michela Gallagher Target for therapy of cognitive impairment
US7599655B2 (en) 2003-01-02 2009-10-06 Qualcomm Incorporated Method and apparatus for broadcast services in a communication system
CN101288260A (zh) 2005-01-27 2008-10-15 美商内数位科技公司 使用未由他人分享联合随机衍生秘钥方法及系统
FR2900936B1 (fr) * 2006-05-15 2013-01-04 Exonhit Therapeutics Sa Procede et methodes de detection de la maladie d'alzheimer
CA2671524A1 (fr) * 2006-12-01 2008-06-12 Loma Linda University Medical Center Inhibition des enzymes cerebrales impliquees dans l'angiopathie amyloide cerebrale et la degeneration maculaire
EP2205249B1 (fr) 2007-09-28 2018-11-07 Intrexon Corporation Constructions et bioréacteurs de commutation de gène théapeutique destinés à l'expression de molécules biothérapeutiques, et utilisation de ceux-ci
WO2013026060A1 (fr) * 2011-08-18 2013-02-21 The Regents Of The University Of California L'oligomère toxique polypeptidique amyloïde d'ilot est un biomarqueur d'une modification du cerveau dans le diabète sucré de type 2
AU2014311258B2 (en) * 2013-08-27 2020-12-17 Crc For Mental Health Ltd Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
BR112017021098A2 (pt) * 2015-04-02 2018-07-03 Crc For Mental Health Ltd método para prever risco de deterioração cognitiva
RU2699057C1 (ru) * 2018-08-30 2019-09-03 Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический Центр дерматовенерологии и косметологии Департамента здравоохранения города Москвы" Способ диагностики нейросифилиса
US20230045629A1 (en) * 2020-01-15 2023-02-09 National University Corporation Tokai National Higher Education And Research System Treatment of progressive supranuclear palsy
WO2021177447A1 (fr) * 2020-03-06 2021-09-10 株式会社カネカ Kit et procédé de détermination de démence ou de fonction cérébrale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4213497A1 (de) * 1992-04-24 1993-10-28 Max Delbrueck Centrum Verfahren zur Herstellung von monoklonalen Antikörpern gegen humanes Interferon-gamma

Also Published As

Publication number Publication date
US20040033563A1 (en) 2004-02-19
IL154093A0 (en) 2003-07-31
US7105485B2 (en) 2006-09-12
JP2004504366A (ja) 2004-02-12
EP1303537A2 (fr) 2003-04-23
WO2002008449A3 (fr) 2002-09-06
DE60123431D1 (de) 2006-11-09
ATE340805T1 (de) 2006-10-15
CA2417134A1 (fr) 2002-01-31
WO2002008449A2 (fr) 2002-01-31
EP1303537B1 (fr) 2006-09-27

Similar Documents

Publication Publication Date Title
CA2269432A1 (fr) Emploi du ho-1 dans les tests diagnostiques et pronostiques pour les maladies neurodegeneratives
AU2001279515A1 (en) Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases
Hausenblas et al. Relationship among sex, imagery and exercise dependence symptoms.
Bromberg et al. Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders
Prigatano et al. Initial disturbances of consciousness and resultant impaired awareness in Spanish patients with traumatic brain injury
Partonen et al. Moclobemide and fluoxetine in treatment of seasonal affective disorder
WO2002096415A3 (fr) Procedes pour traiter la maladie d'alzheimer et/ou pour reguler les niveaux de peptides beta-amyloides chez un sujet
CA2260145A1 (fr) Utilisation de l-acetylcarnitine, de l-isovalerycarnitine, de l-propionylcarnitine pour augmenter les taux de igf-1
CA2391808A1 (fr) Procede de traitement de symptomes de troubles du systeme nerveux central
WO2003040691A3 (fr) Cd40l(cd154) soluble en tant que marqueur pour le diagnostic de maladies d'atherosclerose
Bronisch et al. Depressive neurosis: a long‐term prospective and retrospective follow‐up study of former inpatients
Ferré et al. Communicative clusters after a right-hemisphere stroke: Are there universal clinical profiles?
EP0824917A3 (fr) Utilisation d'un serotonine agoniste du 5-HT1F dans la fabrication d'un médicament pour le traitement ou l'amélioration du rhume ou de la rhinite allergique
Beauchamp-Turner et al. Effects of meditation on stress, health, and affect.
EP2279742A3 (fr) Polytherapie destinee au traitement de troubles immuno-inflammatoires
MY135838A (en) Methods for the treatment of mental disorders
NO981856L (no) Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling av amyotrof lateral sclerose
BR0108360A (pt) Aparelho e método para a produção de uma prótese dentária com um dispositivo tendo um apoio rotativo linear
Aitken Self-concept and functional independence in the hospitalized elderly
Filley et al. Education provides no protection against Alzheimer's disease
Gabriel Dysphoric mood in paranoid psychoses
Tracy et al. Clock drawing in schizophrenia
Meade et al. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk
AU2001282456A1 (en) Method for the diagnosis and follow up of schizophrenia and other mental and neurodegenerative disorders
Ingvar et al. Activity distribution in the cerebral cortex in organic dementia as revealed by measurements of regional cerebral blood flow